Which is better, HAE or IOVA?

On the Buffett-Fit framework, Haemonetics Corporation (HAE) currently grades higher than IOVA — 70/100 (B grade) vs 24/100 (F). That said, "better" depends on which framework you trust — HAE wins on Warren Buffett, Benjamin Graham, Philip Fisher, Peter Lynch, Joel Greenblatt, Charlie Munger, and Terry Smith; IOVA wins on none. The full pillar breakdown is on this page.

Should I buy HAE or IOVA?

This page is an educational comparison, not investment advice. Both HAE and IOVA are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is HAE better than IOVA for value investing?

On the Buffett-style value-investing framework, HAE currently grades higher — 70/100 vs 24/100, a 46-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between HAE and IOVA on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). HAE currently scores 70/100 (B grade); IOVA scores 24/100 (F grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, HAE or IOVA?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. HAE and IOVA are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, HAE or IOVA?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are HAE and IOVA both Healthcare stocks?

Yes — both Haemonetics Corporation (HAE) and Iovance Biotherapeutics, Inc. (IOVA) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this HAE vs IOVA comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Haemonetics

Iovance Biotherapeutics

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

HAE

Haemonetics

Market cap

$2.98B

Sector

Healthcare

IOVA

Iovance Biotherapeutics

Market cap

$1.47B

Sector

Healthcare

Overall winner

Haemonetics HAE

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	HAE	IOVA	Winner
Warren Buffett	70B	24F	HAE
Benjamin Graham	85A	41D	HAE
Philip Fisher

Side-by-side metrics

Metric	HAE	IOVA
Market cap	$2.98B	$1.47B
P/E (TTM)	24.8x	-
EV/EBIT	14.1x	-
ROIC (TTM)	8.37%	-45.33%
Gross margin	55.74%	114.51%
Net margin	7.29%	-123.9%
Revenue CAGR 5y	7.65%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

HAE leads on

ROIC (TTM)8.37%vs -45.33%+118%
Net margin7.29%vs -123.9%+106%
Market cap$2.98Bvs $1.47B+51%

IOVA leads on

More like HAE

HAE vs HALO HAE vs LMAT HAE vs RMD HAE vs LLY HAE vs UTHR HAE vs IDXX

More like IOVA

IOVA vs HALO

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.